BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29063676)

  • 1. X-linked inhibitor of apoptosis inhibition sensitizes acute myeloid leukemia cell response to TRAIL and chemotherapy through potentiated induction of proapoptotic machinery.
    Zhou J; Lu X; Tan TZ; Chng WJ
    Mol Oncol; 2018 Jan; 12(1):33-47. PubMed ID: 29063676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.
    Carter BZ; Mak DH; Schober WD; Dietrich MF; Pinilla C; Vassilev LT; Reed JC; Andreeff M
    Blood; 2008 Apr; 111(7):3742-50. PubMed ID: 18187663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells.
    Tazzari PL; Tabellini G; Ricci F; Papa V; Bortul R; Chiarini F; Evangelisti C; Martinelli G; Bontadini A; Cocco L; McCubrey JA; Martelli AM
    Cancer Res; 2008 Nov; 68(22):9394-403. PubMed ID: 19010914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Embelin sensitizes acute myeloid leukemia cells to TRAIL through XIAP inhibition and NF-κB inactivation.
    Yang T; Lan J; Huang Q; Chen X; Sun X; Liu X; Yang P; Jin T; Wang S; Mou X
    Cell Biochem Biophys; 2015 Jan; 71(1):291-7. PubMed ID: 25358405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia.
    Loeder S; Zenz T; Schnaiter A; Mertens D; Winkler D; Döhner H; Debatin KM; Stilgenbauer S; Fulda S
    Cancer Res; 2009 Dec; 69(23):8977-86. PubMed ID: 19920200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas.
    Giaisi M; Köhler R; Fulda S; Krammer PH; Li-Weber M
    Int J Cancer; 2012 Aug; 131(4):1003-8. PubMed ID: 21952919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of XIAP in resistance to TNF-related apoptosis-inducing ligand (TRAIL) in Leukemia.
    Saraei R; Soleimani M; Movassaghpour Akbari AA; Farshdousti Hagh M; Hassanzadeh A; Solali S
    Biomed Pharmacother; 2018 Nov; 107():1010-1019. PubMed ID: 30257312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.
    Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Bhanot U; Hasel C; Möller P; Gschwend JE; Simmet T; Debatin KM; Fulda S
    Cancer Res; 2009 Mar; 69(6):2425-34. PubMed ID: 19258513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
    Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
    Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phorbol ester-induced PKCepsilon down-modulation sensitizes AML cells to TRAIL-induced apoptosis and cell differentiation.
    Gobbi G; Mirandola P; Carubbi C; Micheloni C; Malinverno C; Lunghi P; Bonati A; Vitale M
    Blood; 2009 Mar; 113(13):3080-7. PubMed ID: 18988868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells.
    Metwalli AR; Khanbolooki S; Jinesh G; Sundi D; Shah JB; Shrader M; Choi W; Lashinger LM; Chunduru S; McConkey DJ; McKinlay M; Kamat AM
    Cancer Biol Ther; 2010 Nov; 10(9):885-92. PubMed ID: 20814238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homoharringtonine and SAHA synergistically enhance apoptosis in human acute myeloid leukemia cells through upregulation of TRAIL and death receptors.
    Cao H; Cheng Y; You L; Qian J; Qian W
    Mol Med Rep; 2013 Jun; 7(6):1838-44. PubMed ID: 23620163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells.
    Yano K; Horinaka M; Yoshida T; Yasuda T; Taniguchi H; Goda AE; Wakada M; Yoshikawa S; Nakamura T; Kawauchi A; Miki T; Sakai T
    Int J Oncol; 2011 Feb; 38(2):365-74. PubMed ID: 21165560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.
    Mori T; Doi R; Kida A; Nagai K; Kami K; Ito D; Toyoda E; Kawaguchi Y; Uemoto S
    J Surg Res; 2007 Oct; 142(2):281-6. PubMed ID: 17640673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein.
    Karikari CA; Roy I; Tryggestad E; Feldmann G; Pinilla C; Welsh K; Reed JC; Armour EP; Wong J; Herman J; Rakheja D; Maitra A
    Mol Cancer Ther; 2007 Mar; 6(3):957-66. PubMed ID: 17339366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.
    Chamuleau ME; Ossenkoppele GJ; van Rhenen A; van Dreunen L; Jirka SM; Zevenbergen A; Schuurhuis GJ; van de Loosdrecht AA
    Leuk Res; 2011 Jun; 35(6):741-9. PubMed ID: 21281967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis.
    Frenzel LP; Patz M; Pallasch CP; Brinker R; Claasen J; Schulz A; Hallek M; Kashkar H; Wendtner CM
    Br J Haematol; 2011 Jan; 152(2):191-200. PubMed ID: 21091905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Embelin potentiates venetoclax-induced apoptosis in acute myeloid leukemia cells.
    Reis-Silva CSM; Branco PC; Lima K; Silva FL; Moreno PRH; Guallar V; Costa-Lotufo LV; Machado-Neto JA
    Toxicol In Vitro; 2021 Oct; 76():105207. PubMed ID: 34216723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
    Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
    Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL.
    Symanowski J; Vogelzang N; Zawel L; Atadja P; Pass H; Sharma S
    J Thorac Oncol; 2009 Feb; 4(2):149-60. PubMed ID: 19179889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.